Autoimmune Diseases  >>  Dirucotide (MBP8298)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dirucotide (MBP8298) / Eli Lilly
MAESTRO-03, NCT00468611: Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Terminated
3
510
US
MBP8298
BioMS Technology Corp.
Multiple Sclerosis, Secondary Progressive
07/09
09/09
MAESTRO-01, NCT00869726: A Study for Patients With Secondary Progressive Multiple Sclerosis

Completed
2/3
596
Canada, Europe
dirucotide, MBP8298, LY2820671, Placebo
Eli Lilly and Company, BioMS Technology Corp.
Secondary Progressive Multiple Sclerosis
05/09
05/09
MINDSET01, NCT00869986 / 2006-001947-70: A Study for Patients With Relapsing Remitting Multiple Sclerosis

Completed
2/3
218
Europe, RoW
dirucotide, MBP8298, LY2820671, placebo
Eli Lilly and Company, BioMS Technology Corp.
Relapsing Remitting Multiple Sclerosis
09/09
09/09
MAESTRO-02, NCT00870155: A Study for Patients With Multiple Sclerosis

Terminated
2/3
546
Canada, Europe
dirucotide, MBP8298, LY2820671
Eli Lilly and Company, BioMS Technology Corp.
Secondary Progressive Multiple Sclerosis
09/09
09/09

Download Options